Japan's pharma market is one of the world's biggest, with a value of around USD 95 billion, according to figures from the country's Ministry of…

A newly formed ‘Plasma Alliance’ of the world’s leading blood plasma companies believed that plasma from those who have recovered from COVID-19…

IFPMA Director General Thomas B. Cueni shares the outcomes of a recent high level pharma industry media briefing on the search for a COVID-19…

Accounting for less than two percent of the global pharmaceutical market, the Middle East has long been somewhat overlooked by many drug makers, most…

Despite the challenging characteristics of the Romanian market, with a large population of nearly 20 million people and significant unmet medical…

Sweden’s USD 4.8 billion pharmaceutical market, its population size of 10 million and marginal positioning on the northerly fringe of the European…

The CEOs and top executives, David Ricks, chairman and CEO, Eli Lilly & Co and IFPMA president, Severin Schwan, CEO, Roche, Paul Stoffels, chief…

Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or…

A cross-industry push for better and broader access to innovative treatments is underway in the Czech Republic. Ripe for reform is the country’s…

Dominika Kovacs, country manager of Takeda Romania, shares her insights on the growing pipeline of the organisation and the anticipated launch of a…

With nearly 240 years of history behind it, Takeda continues to position itself as a leading global R&D-driven biopharmaceutical organization. Dr…

Kieran Leahy, general manager of Takeda in the Czech Republic and Slovakia, recounts how he has led the transformation of Takeda into a specialty care…